Zonisamide ODT Formulation Strength Disintegration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing orally disintegrating tablets (ODTs) of zonisamide face challenges in achieving high mechanical resistance while maintaining quick disintegration times, often requiring complex and energy-intensive processes, and using non-standard excipients that increase costs and complexity.
Innovation Solution
The development of ODTs using direct compression with a formulation comprising zonisamide, mannitol, microcrystalline cellulose, carmellose, crospovidone, and a lubricant, which provides high hardness and rapid disintegration, and can be manufactured using simple machinery with lower economic and energetic costs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If conventional compaction technologies with superdisintegrants are used, then disintegration is accelerated, but tablet mechanical resistance decreases
Solution Approach 1:
The patent uses a composite granule formulation containing multiple excipients (microcrystalline cellulose, crospovidone, mannitol, povidone) that work synergistically to provide both mechanical strength and rapid disintegration. The granules are compressed into tablets that maintain high mechanical resistance while achieving disintegration times under 30 seconds, resolving the contradiction between strength and disintegration rate.
2Speed
If freeze drying technology is used, then quick disintegration is achieved, but manufacturing complexity and cost increase
Solution Approach 1:
The patent extracts the disintegration function from the manufacturing process itself and incorporates it into the tablet formulation through the granule composition. Instead of using freeze drying to create porous structures, the patent uses chemically bonded granules with inherent disintegration properties that achieve rapid disintegration through conventional compression, eliminating complex freeze drying equipment.
Solution Approach 2:
The patent replaces expensive freeze drying technology with conventional compression technology using specially formulated granules. The granules are designed to be compressed directly into tablets that disintegrate rapidly, using simple, widely available equipment rather than specialized freeze drying machinery, thereby reducing manufacturing complexity and cost.
3Strength
If RACTAB technology with multiple excipients is used, then tablet hardness is improved, but manufacturing time and energy consumption increase
Solution Approach 1:
The patent merges multiple functions into a single granulation step. The granules contain microcrystalline cellulose for structural integrity, crospovidone for disintegration, and mannitol for hardness enhancement, all incorporated together rather than through sequential processing steps. This unified approach achieves high tablet hardness and rapid disintegration in one manufacturing pass, reducing time and energy consumption.
4Speed
If molding technology is used, then rapid dissolution is achieved, but tablet mechanical resistance decreases
Solution Approach 1:
The patent changes the physical parameters of the granules, specifically their size distribution (D10: 30-50 μm, D50: 70-90 μm, D90: 100-150 μm) and composition, to achieve both rapid dissolution and high mechanical resistance. The controlled particle size and chemical bonding in the granules enable fast dissolution while the compression process creates tablets with adequate hardness, resolving the contradiction between dissolution rate and mechanical strength.
Data Source
AI summary
The present invention relates to solid pharmaceutical formulations comprising zonisamide as an active ingredient, in particular it relates to a tablet for oral administration of zonisamide which disintegrates rapidly in the oral cavity, has good mechanical strength properties and is obtainable by conventional manufacturing methods.